BG105666A - Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex - Google Patents

Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex

Info

Publication number
BG105666A
BG105666A BG105666A BG10566601A BG105666A BG 105666 A BG105666 A BG 105666A BG 105666 A BG105666 A BG 105666A BG 10566601 A BG10566601 A BG 10566601A BG 105666 A BG105666 A BG 105666A
Authority
BG
Bulgaria
Prior art keywords
complex
cyclodextrin
beta
ras
sulfobutylether
Prior art date
Application number
BG105666A
Other languages
Bulgarian (bg)
English (en)
Inventor
Krishnaswamy Raghavan
Timothy Malloy
Sailesh Varia
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BG105666A publication Critical patent/BG105666A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG105666A 1999-01-21 2001-07-03 Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex BG105666A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11664799P 1999-01-21 1999-01-21
PCT/US1999/030424 WO2000042849A1 (en) 1999-01-21 1999-12-21 COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-β-CYCLODEXTRIN OR 2-HYDROXYPROPYL-β-CYCLODEXTRIN AND METHOD

Publications (1)

Publication Number Publication Date
BG105666A true BG105666A (en) 2002-04-30

Family

ID=22368422

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105666A BG105666A (en) 1999-01-21 2001-07-03 Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex

Country Status (33)

Country Link
US (1) US6218375B1 (xx)
EP (1) EP1143796A4 (xx)
JP (1) JP2002535253A (xx)
KR (1) KR100708360B1 (xx)
CN (1) CN1219517C (xx)
AR (1) AR022323A1 (xx)
AU (1) AU772204B2 (xx)
BG (1) BG105666A (xx)
BR (1) BR9916566A (xx)
CA (1) CA2359646C (xx)
CO (1) CO5160253A1 (xx)
CZ (1) CZ20012601A3 (xx)
EE (1) EE200100382A (xx)
GE (1) GEP20043214B (xx)
HK (1) HK1038865A1 (xx)
HU (1) HUP0105160A3 (xx)
ID (1) ID30139A (xx)
IL (1) IL144025A (xx)
LT (1) LT4893B (xx)
LV (1) LV12712B (xx)
MY (1) MY119700A (xx)
NO (1) NO20013585L (xx)
NZ (1) NZ511995A (xx)
PE (1) PE20001419A1 (xx)
PL (1) PL195280B1 (xx)
RU (1) RU2230062C2 (xx)
SK (1) SK9602001A3 (xx)
TR (1) TR200102109T2 (xx)
TW (1) TWI232752B (xx)
UA (1) UA67825C2 (xx)
UY (2) UY25987A1 (xx)
WO (1) WO2000042849A1 (xx)
ZA (1) ZA200104416B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
US6566347B1 (en) * 2001-08-22 2003-05-20 Duquesne University Of The Holy Ghost Controlled release pharmaceutical
WO2003041658A2 (en) * 2001-11-13 2003-05-22 Bristol-Myers Squibb Company Process for the preparation of 3,7-disubstituted-2,3,4,5- tetrahydro-1h-1,4-benzodiazepine compounds
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
AU2003276648A1 (en) * 2002-06-17 2003-12-31 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f¿1?f¿0? atp hydrolase and methods of inhibiting f¿1?f¿0? atp hydrolase
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
JP5284096B2 (ja) 2005-09-30 2013-09-11 ルンドベック エルエルシー 新規非経口カルバマゼピン製剤
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
TW200806284A (en) * 2006-03-31 2008-02-01 Alcon Mfg Ltd Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
JP2010510311A (ja) * 2006-11-21 2010-04-02 ノバルティス アーゲー ベンゾジアゼピン構造のｒｓｖ阻害剤を含む安定な非経腸製剤
JP5600111B2 (ja) 2008-10-22 2014-10-01 アレイ バイオファーマ、インコーポレイテッド ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物
AU2011258964B2 (en) 2010-05-26 2015-04-16 Neurophyxia B.V. 2-iminobiotin formulations and uses thereof
WO2012034038A2 (en) 2010-09-09 2012-03-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dual inhibitors of farnesyltransferase and geranylgeranyltransferase i
JP6165744B2 (ja) * 2011-10-07 2017-07-19 パイシーズ セラピューティックス エルエルシーＰｉｓｃｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｌｃ Ｒａｓアンタゴニストによる悪性および非悪性疾患の治療
CN105194685A (zh) * 2015-10-15 2015-12-30 重庆大学 磺胺脒的磺丁基醚-β-环糊精包合物及其粉针制剂
PL3389653T3 (pl) 2015-12-16 2024-02-26 Neurophyxia B.V. 2-iminobiotyna do zastosowania w leczeniu uszkodzeń komórek mózgowych
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
TN2018000335A1 (en) 2016-04-04 2020-01-16 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
PL3800189T3 (pl) 2016-05-18 2023-10-23 Loxo Oncology, Inc. Wytwarzanie (s)-n-(5-((r)-2-(2,5-difluorofenylo)pirolidyn-1-ylo)pirazolo[1,5-a]pirymidyn-3-ylo)-3-hydroksypirolidyno-1-karboksyamidu
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US20210145816A1 (en) * 2019-11-15 2021-05-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin
CA3240887A1 (en) * 2021-12-15 2023-06-22 Luc BURY Pharmaceutical compositions comprising modified beta-cyclodextrins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5630927A (en) * 1979-08-24 1981-03-28 Zeria Shinyaku Kogyo Kk Stabilization of guaiazulene and its derivative
US4371673A (en) * 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH07165616A (ja) * 1993-12-09 1995-06-27 Hisamitsu Pharmaceut Co Inc シクロデキストリンの複合組成物及び複合化法
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
JPH1067639A (ja) * 1996-08-26 1998-03-10 Shiseido Co Ltd ビタミンｅ−ビタミンｃリン酸ジエステル／シクロデキストリン包接物及び該包接物を配合した皮膚外用剤

Also Published As

Publication number Publication date
US6218375B1 (en) 2001-04-17
CZ20012601A3 (cs) 2002-05-15
CO5160253A1 (es) 2002-05-30
PL366338A1 (en) 2005-01-24
AR022323A1 (es) 2002-09-04
NZ511995A (en) 2003-11-28
NO20013585L (no) 2001-09-04
JP2002535253A (ja) 2002-10-22
HK1038865A1 (zh) 2002-04-04
CN1333651A (zh) 2002-01-30
RU2230062C2 (ru) 2004-06-10
ID30139A (id) 2001-11-08
GEP20043214B (en) 2004-04-26
PL195280B1 (pl) 2007-08-31
HUP0105160A3 (en) 2003-01-28
IL144025A (en) 2004-05-12
CA2359646C (en) 2008-12-02
UY25987A1 (es) 2000-09-29
UY25986A1 (es) 2000-09-29
TR200102109T2 (tr) 2001-12-21
EP1143796A4 (en) 2002-03-20
KR20010101611A (ko) 2001-11-14
ZA200104416B (en) 2002-05-29
UA67825C2 (uk) 2004-07-15
EP1143796A1 (en) 2001-10-17
TWI232752B (en) 2005-05-21
CA2359646A1 (en) 2000-07-27
LV12712A (lv) 2001-09-20
KR100708360B1 (ko) 2007-04-17
IL144025A0 (en) 2002-04-21
LT2001064A (en) 2001-10-25
HUP0105160A2 (hu) 2002-05-29
SK9602001A3 (en) 2002-06-04
BR9916566A (pt) 2001-11-13
NO20013585D0 (no) 2001-07-20
MY119700A (en) 2005-06-30
EE200100382A (et) 2002-12-16
AU772204B2 (en) 2004-04-22
LT4893B (lt) 2002-02-25
AU2374000A (en) 2000-08-07
LV12712B (en) 2002-01-20
PE20001419A1 (es) 2001-02-21
CN1219517C (zh) 2005-09-21
WO2000042849A1 (en) 2000-07-27

Similar Documents

Publication Publication Date Title
BG105666A (en) Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex
MY118904A (en) 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents
NL300927I1 (nl) tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
MXPA04004037A (es) Compuestos novedosos de 1, 2, 4-de triazol.
CA2107014A1 (en) Therapeutic Agent for Parkinson's Disease
CA2547947A1 (en) Azole derivatives as active superoxide radical inhibitors
BG106585A (en) Kinase inhibitors as therapeutic agents
PT1076663E (pt) Derivados funcionalizados de alquilo e alcenilo de cadeia lateral de glicinamidas como inibidores de farnesil transferase
NO931433D0 (no) 4,1-benzoksazepinderivater og deres anvendelse
RS20050182A (xx) DERIVATI DIOKSAN-2- ALKILKARBAMATA,POSTUPAK ZA NjIHOVO DOBIJANjE I PRIMENA ISTIH U TERAPEUTICIMA
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
GB9908410D0 (en) Pyridines
YU21100A (sh) Izohinolini kao urokinazni inhibitori
PL341050A1 (en) Heterocyclic cytoxic agents
AR044175A1 (es) Compuestos de cefemo
TW427993B (en) New cephem compounds
BG103735A (en) Method for the preparation of substituted thiazolidindions
TW350838B (en) Quinoline derivatives
MXPA02003952A (es) Derivados de imidazol como inhibidores de la fosfodieterasa vii.
MY109714A (en) Process for preparing 8-chloroquinolone derivatives
EP0315434A3 (en) Pyridoxal hydrazone derivatives their production and use and pharmaceutical compositions containing the same
BG106048A (en) 6-[[(aryl and heteroaryl)oxy]methyl]naphthalene-2-carboximidamide derivatives, preparation and therapeutic application thereof
AU2002244985A1 (en) Thiazolidinedione derivatives and pharmaceutical composition comprising the same
WO2002033216A3 (en) Corrosion inhibitor-drag reducer combinations
ECSP003322A (es) COMPLEJO DEL INHIBIDOR DE RAS- FARNESIL TRANSFERASA Y SULFOBUTILETER -7-ß- CICLODEXTRINA O 2- HIDROXIPROPIL - ß - CICLODEXTRINA Y METODO